WITHDRAWN: Reply to "Smoker, Former Smoker and COVID-19: Nicotine Does Not Protect Against SARS-CoV-2"

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal

Respuesta a "Fumador, exfumador y COVID-19" / Reply to "Smoker, Former Smoker and COVID-19"

No disponible

Certified Smoking Cessation Units in Spain: High Potential for Detection of Undiagnosed Chronic Obstructive Pulmonary Disease and Profile of Newly Diagnosed Cases.

PURPOSE: Smokers attending smoking cessation units (SCUs) may offer a unique opportunity for early recognition of undiagnosed chronic obstructive pulmonary disease (COPD). We aimed at assessing the impact of SCUs on the early diagnosis of COPD and describing the clinical and smoking profile of newly-diagnosed COPD cases at SCUs certified by the Spanish Society of Respiratory Diseases and Thoracic Surgery (SEPAR). PATIENTS AND METHODS: A multicenter cross-sectional observational cohort study (DIPREPOQ study) was performed in eight SEPAR-certified SCUs in Spain. Adult current smokers with no previously diagnosed respiratory disease and having one o more respiratory symptoms were included. Lung functional tests were performed and previously undiagnosed COPD cases were identified and characterized based on national guidelines. RESULTS: Out of 401 individuals newly attending the SCUs, 252 participants were included and 73 (28.9%) met the definition of previously undiagnosed COPD. A characterization of patients with COPD being newly recognized in SCUs showed: age (mean±SD) 61±9 years; men 59%; active work status 53.1%; functional class I/II dyspnea 82.8%, GOLD state mild/moderate/severe 57%/31%/12%; non-exacerbators 90%, CAT 14±4; emphysema in X-rays 40%. Most common co-morbidities were cardiovascular and psychiatric (anxiety and depression) ones. Usual smoking history included a lengthy smoking history (41±9 years) and a current consumption of 24±9 cigarettes/day. CONCLUSIONS AND IMPLICATIONS: Consistently certified SCUs can have a substantial contribution to early diagnosis of COPD. A typical profile of newly detected cases is reported, with most patients being men at their early sixties, with mild symptoms and with high and lengthy smoking history. Our study reports a high usefulness of lung functional tests to detect undiagnosed COPD in appropriately selected participants attending SCUs at a large national scale, using a standardized methodology. This is likely to be facilitated by the certification of SCUs using well-defined requirements by national scientific societies.

Posicionamiento de la Organización Mundial de la Salud. Impacto del tabaco en el medio ambiente: cultivo, curado, manufactura, transporte y tabaquismo de tercera y cuarta mano / World Health Organization positioning. The Impact of Tobacco in the Environment: Cultivation, Curing, Manufacturing, Transport, and Third and Fourth-hand Smoking

No disponible

Patología pulmonar asociada al consumo de marihuana / Lung disease associated with marijuana use

La marihuana es la droga ilícita más consumida en el mundo con prevalencia de 2,5 a 5% y la segunda sustancia fumada después del tabaco. Los componentes del humo por la combustión de esta sustancia son similares a los producidos en la combustión del tabaco, pero difieren en la sustancia psicoactiva y en la práctica de fumar. La inhalación del humo de cannabis produce consecuencias sobre el aparato respiratorio. Por ello se hace necesario actualizar la evidencia disponible para ofrecer información científica al neumólogo. En este artículo se revisa el impacto del consumo de cannabis en los pulmones, teniendo en cuenta que la ruta más popular de la ingestión de cannabis es a través de las vías respiratorias (AU)

Marijuana is the most widely used illegal drug in the world, with a prevalence of 2.5%-5%, and the second most commonly smoked substance after tobacco. The components of smoke from combustion of marijuana are similar to those produced by the combustion of tobacco, but they differ in terms of psychoactive components and use. Inhalation of cannabis smoke affects the respiratory tract, so the available evidence must be updated in order to provide pulmonologists with the latest scientific information. In this article, we review the impact of cannabis consumption on the lungs, taking into account that the respiratory route is the most popular route of cannabis consumption (AU)

Lung Disease Associated With Marijuana Use. / Patología pulmonar asociada al consumo de marihuana.

Marijuana is the most widely usedillegal drug in the world, with a prevalence of 2.5%-5%, and the second most commonly smoked substance after tobacco. The components of smoke from combustion of marijuana are similar to those produced by the combustion of tobacco, but they differ in terms of psychoactive components and use. Inhalation of cannabis smoke affects the respiratory tract, so the available evidence must be updated in order to provide pulmonologists with the latest scientific information. In this article, we review the impact of cannabis consumption on the lungs, taking into account that the respiratory route is the most popular route of cannabis consumption.

Informe sobre el control del tabaquismo en los países ibero-latino-americanos / Report on the control of smoking in ibero-latin-american countries

No disponible

Intervenciones en tabaquismo en pacientes con enfermedades cardiovasculares / Smoking intervention in patients with cardiovascular diseases

El tabaco es el principal factor de riesgo cardiovascular, presentando, además, una relación dosis–respuesta. Se ha comprobado que una política agresiva, no solo contra el consumo, consigue una disminución significativa en la mortalidad cardiovascular. Debemos, por lo tanto, facilitar y realizar acciones dirigidas a impedir o disminuir la incidencia del tabaquismo (prevención primaria), a la detección precoz del fumador y a reducir la prevalencia (prevención secundaria) y, por último, a actuar sobre los efectos del humo del tabaco evitando complicaciones y recaídas (prevención terciaria). Por ello, desde todos los niveles asistenciales de nuestro sistema de salud se debe intervenir para que los fumadores no desarrollen enfermedades, así como para que los pacientes con enfermedades cardiovasculares dejen de fumar, tanto desde la atención primaria como desde la especializada(AU)

Smoking tobacco is the main cardiovascular risk factor and has a dose-dependent response. It has been shown that an aggressive policy, not only against consumption, achieves a significant decrease in cardiovascular deaths. Thus, we must provide and carry out activities to prevent or decrease the incidence of smoking (primary prevention), and to the early detection of the smoker and to reduce the prevalence (secondary prevention), and lastly to act on the effects of tobacco smoke, preventing complication and remissions (tertiary prevention). Thus, all health care levels must act in order that smokers do not develop cardiovascular disease when they quit smoking, both from Primary, as well as specialist care(AU)

[Smoking intervention in patients with cardiovascular diseases]. / Intervenciones en tabaquismo en pacientes con enfermedades cardiovasculares.

Smoking tobacco is the main cardiovascular risk factor and has a dose-dependent response. It has been shown that an aggressive policy, not only against consumption, achieves a significant decrease in cardiovascular deaths. Thus, we must provide and carry out activities to prevent or decrease the incidence of smoking (primary prevention), and to the early detection of the smoker and to reduce the prevalence (secondary prevention), and lastly to act on the effects of tobacco smoke, preventing complication and remissions (tertiary prevention). Thus, all health care levels must act in order that smokers do not develop cardiovascular disease when they quit smoking, both from Primary, as well as specialist care.

Algunas consideraciones sobre el tabaco de liar / Some Thoughts on Hand-Rolled Cigarette

No disponible

Abandono del tabaquismo: un componente esencial en el tratamiento del paciente con cáncer de pulmón / Smoking Cessation: An Essential Component in the Treatment of Lung Cancer Patients

No disponible

Comparación entre dos quinquenios (1998/2002 y 2003/2007) de la producción, repercusión y colaboración en tabaquismo de autores españoles a través del Science Citation Index / Comparison Between Two Five Year Periods (1998/2002 and 2003/2007) on the Production, Impact and co-Authorship of Publications on Tobacco and Smoking by Spanish authors Using the Science Citation Index

ObjetivoEl objetivo ha sido comparar entre dos quinquenios (1998 a 2002 con 2003 a 2007) la producción, repercusión y la colaboración de artículos sobre tabaquismo de autores españoles a través del Science Citation Index (SCI).MétodoLa búsqueda se realizó en el SCI Expanded. Fueron seleccionados todos los tipos de documentos y la búsqueda se restringió al “título”; palabras clave: “smok*” y “tobac*”.ResultadosFueron un total de 588 artículos, de los que 399 (67,85%) fueron originales, 54 (9,18%) cartas al director y 35 (5,95%) editoriales. La producción ha crecido, pasando de 234 (39,8%) documentos (98/02) a 354 (60,2%) en 03/07. Al comparar la media anual del total de artículos por quinquenios 98/02 vs 03/07 (47±8 vs 71±16 [p=0,024]) la diferencia es significativa, igual que si comparamos las medias anuales por quinquenios de los originales (34±6 vs 46±9 [p=0,041]). La media de citas/trabajo por quinquenios fue de 14,1±2,1 para 98/02 y del 5,6±2,5 para 03/07 (p=0,003). El índice de colaboración anual aumentó, pasando la media de 6,77 firmas/trabajo en 98/02, a 6,87 firmas/trabajo en 03/07. Ha aumentado el número de redes de colaboración de instituciones y autores.ConclusionesTanto la producción científica como la colaboración entre autores e instituciones han aumentado en el periodo estudiado. Son los artículos más antiguos los que más citas tienen(AU)

ObjectiveThe aim of this study was to compare the production, impact and co-authorship of publications by Spanish authors on smoking and tobacco between two time periods (1998/2002 vs 2003/2007) using Science Citation Index (SCI).MethodsThe literature search was performed in the SCI-Expanded on 20 November 2008. All types of documents by Spanish authors were selected. The search was restricted to the title, and the key words used were “smok*” and “tobac*”. The statistical analysis was descriptive (95% CI).ResultsA total of 588 documents were obtained, with 399 (67.85%) original papers, 54 (9.18%) letters to the editor, and 35 (5.95%) editorials. Productivity increased between the 98/02 to 03/07 periods: 234 (39.8%) documents versus 354 (60.2%). We have found significant differences between the two periods (98/02 vs 03/07) in total mean annual documents (47±8 vs 71±16 [p=0.024]) and total mean annual original papers (34±6 vs 46±9 [p=0.041]). The mean number of citations per document was 14.1±2.1 for 98/02 period and 5.6±2.5 for 03/07 period (p=0.003). The co-authorship annual index had increased; with a mean of 6.77 signatures/document for 98/02 period to a mean of 6.87 for 03/07 period. Authors and institution networks collaborations had increased between the two periods.ConclusionsSpanish production and co-authorship of documents on smoking and tobacco have increased between these two periods. The earlier period documents received more citations(AU)